Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCP2 | P22307 | 1/20 | 0.72 |
| ▸ | GPR84 | Q9NQS5 | 10/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ACSL1 | P33121 | 2/20 | 0.41 |
| ▸ | ACSL6 | Q9UKU0 | 2/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14267415 | 0.88 | SCP2 (0.56) | SCP2GPR84MEN1NPC1POLB | |
| SCHEMBL4662802 | 0.88 | SCP2 (0.56) | SCP2GPR84MEN1NPC1POLB | |
| SCHEMBL14267417 | 0.84 | SCP2 (1.00) | SCP2GPR84MEN1NPC1POLB | |
| SCHEMBL7812704 | 0.82 | SCP2 (0.93) | SCP2GPR84MEN1NPC1POLB | |
| SCHEMBL14267412 | 0.81 | MEN1 (0.49) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL15398240 | 0.79 | MEN1 (0.64) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL4664338 | 0.78 | MEN1 (0.52) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL4663120 | 0.75 | MEN1 (0.48) | SCP2MEN1NPC1POLBRAB9A | |
| SCHEMBL7815701 | 0.74 | SCP2 (0.79) | SCP2GPR84MEN1NPC1POLB | |
| SCHEMBL3501312 | 0.74 | SCP2 (0.82) | SCP2GPR84MEN1NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080038840-A1 | Fluorescent Method And Compounds To Monitor Protein-Lipid Binding | EUROPAEISCHES LABORATORIUM FUER MOLEKULARBIOLOGIE (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080038840-A1 | Fluorescent Method And Compounds To Monitor Protein-Lipid Binding | EUROPAEISCHES LABORATORIUM FUER MOLEKULARBIOLOGIE (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080038840-A1 | Fluorescent Method And Compounds To Monitor Protein-Lipid Binding | EUROPAEISCHES LABORATORIUM FUER MOLEKULARBIOLOGIE (DE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038840-A1 | Fluorescent Method And Compounds To Monitor Protein-Lipid Binding | DBI, CETP, SREBF1 | SCP2 34/4885GPR84 1678/4885MEN1 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.